Wang-Gohrke S - Search Results

1

p53 germline polymorphisms are associated with an increased risk for breast cancer in German women.

Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. Wang-Gohrke S, et al. Anticancer Res. 1998 May-Jun;18(3B):2095-9. Anticancer Res. 1998. PMID: 9677474

2

Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples.

Wang-Gohrke S, Hees S, Pochon A, Wen WH, Reles A, Press MF, Kreienberg R, Runnebaum IB. Wang-Gohrke S, et al. Oncol Rep. 1998 Jan-Feb;5(1):65-8. doi: 10.3892/or.5.1.65. Oncol Rep. 1998. PMID: 9458295

3

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.

Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Wang-Gohrke S, et al. Br J Cancer. 1999 Sep;81(1):179-83. doi: 10.1038/sj.bjc.6690669. Br J Cancer. 1999. PMID: 10487631 Free PMC article.

4

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.

Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Wang-Gohrke S, et al. Cancer Res. 2000 May 1;60(9):2348-50. Cancer Res. 2000. PMID: 10811106

5

Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3.

Brüning A, Köhler T, Quist S, Wang-Gohrke S, Moebus VJ, Kreienberg R, Runnebaum IB. Brüning A, et al. Hum Gene Ther. 2001 Mar 1;12(4):391-9. doi: 10.1089/10430340150504019. Hum Gene Ther. 2001. PMID: 11242531

6

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA. Runnebaum IB, et al. Pharmacogenetics. 2001 Oct;11(7):635-8. doi: 10.1097/00008571-200110000-00010. Pharmacogenetics. 2001. PMID: 11668223

7

Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years.

Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Wang-Gohrke S, et al. Pharmacogenetics. 2002 Apr;12(3):269-72. doi: 10.1097/00008571-200204000-00012. Pharmacogenetics. 2002. PMID: 11927843

8

Interaction between alcohol dehydrogenase II gene, alcohol consumption, and risk for breast cancer.

Stürmer T, Wang-Gohrke S, Arndt V, Boeing H, Kong X, Kreienberg R, Brenner H. Stürmer T, et al. Br J Cancer. 2002 Aug 27;87(5):519-23. doi: 10.1038/sj.bjc.6600500. Br J Cancer. 2002. PMID: 12189549 Free PMC article.

9

Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.

Quist SR, Wang-Gohrke S, Köhler T, Kreienberg R, Runnebaum IB. Quist SR, et al. Cancer Gene Ther. 2004 Aug;11(8):547-54. doi: 10.1038/sj.cgt.7700727. Cancer Gene Ther. 2004. PMID: 15153938

10

Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany.

Wang-Gohrke S, Chang-Claude J. Wang-Gohrke S, et al. Breast Cancer Res Treat. 2004 Dec;88(3):231-7. doi: 10.1007/s10549-004-0782-5. Breast Cancer Res Treat. 2004. PMID: 15609125

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results